ArticleBMJ health & care informatics2026
Towards a feature-based regulatory benchmark for user-centred SaMD design in cancer care.
Article in BMJ health & care informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Software as a medical device (SaMD) is increasingly central to cancer care, yet current regulatory frameworks from the International Medical Device Regulators, the US Food and Drug Administration and the European Medical Device Regulation lack clear premarket standards for evaluating usability, accessibility and emotional/cultural appropriateness for intended users. This gap is particularly problematic in oncology, where patients, caregivers and clinicians navigate high cognitive load, emotional stress and complex care coordination that can make poorly designed tools ineffective or even harmful.This paper introduces a structured, feature-based benchmark grounded in human-centred design and user-centred design principles to address this critical gap and enable integration into early regulatory review. The benchmark defines measurable design criteria for premarket review, with a focus on usability, accessibility, emotional safety and clinical applicability, providing both developers and regulators with a practical checklist. By embedding these standards early in the product lifecycle, the framework supports regulatory consistency, reduces postmarket usability failures and improves patient trust, engagement and clinical outcomes.While developed for oncology care, the benchmark principles are adaptable across diseases, offering a replicable pathway to align SaMD design with both clinical requirements and the real-world needs of patients and healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.